Metastudie;Doi;Titel;Publikationsjahr;Anzahl Studien;Studienname;Publikationsjahr;Geschlecht;Index_Geschlecht;Alter.Text;Alter;Alter.gewichte;Alterrange;;;;Gesamt 159;;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Alekseeva;2000;;not reported;"60 patients with type 2 diabetes (30 in each arm)
30 patients in a further treatment arm receiving linseed oil measuring lipid markers";not reported;;;;;76;https://doi.org/10.1002/14651858.CD003287.pub4;"For studies in type 1 diabetes patients the incidence of severe hypoglycaemia ranged from 0 to 247.3 (median 21.8) episodes per 100 person?years for insulin analogues and from 0 to 544 (median 46.1) for regular insulin, in type 2 the incidence ranged from 0 to 30.3 (median 0.3) episodes per 100 person?years for insulin analogues and from 0 to 50.4 (median 1.4) for regular insulin; NUMBER: I:Type 1: 162 vs. 174; II:Type 2: 145 vs. 150 Type 2 (lispro vs. regular); TYPE OF DIABETES: 1 and 2; MEAN AGE [YEARS]: Type 1: 32 vs. 32; Type 2: 56 vs. 56 (lispro vs. regular)  ";;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Annuzzi;1991;8 male patients with type 2 diabetes;male;;not reported;;;;;80;https://doi.org/10.1002/14651858.CD009951.pub3;title: Probiotics for preventing gestational diabetes;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Axelrod;1994;;not reported;"20 ambulatory participants (10 in each arm, 9 in each arm for final analysis) 
with type 2 diabetes";not reported;;;;;63;https://doi.org/10.1002/14651858.CD008474.pub2;Adults (over 18 years of age) with type 1 or type 2 DM, and with an active foot ulcer of neuropathic, neuroischaemic or ischaemic aetiology.;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Boberg;1992;;not reported;14 participants (86% male) with type 2 diabetes;not reported;;;;;115;https://doi.org/10.1002/14651858.CD006763.pub2;We included all randomised controlled trials of salt reduction in individuals with type 1 and type 2 diabetes.;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Borkman;1989;10 participants (70% male);both;"10 participants (70% male, 57ñ6.3 years old) with mild type 2 diabetes 
for 3.5ñ2.8 years of disease. (7 in the final analysis for HDL and LDL).";57;;;;;135;https://doi.org/10.1002/14651858.CD010564.pub2;"Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes; Inlcusion criteria: pregnant women with BMI ? 30 kg/m2, and normal glucose tolerance test";;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Connor ;1993;16 participants (81% male);both;16 participants (81% male, 58.7ñ8 years?old) with type 2 diabetes;58,7;;;;;131;https://doi.org/10.1002/14651858.CD007669.pub2;"Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients; Pancreas or kidney?pancreas transplantation improves survival and quality of life for people with type 1 diabetes mellitus and kidney failure";;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Goh ;1997;;not reported;"28 people with type 2 diabetes were divided into a low polyunsaturated/saturated 
fat and a high polyunsaturated/saturated fat diet group. Each group was then randomized to each crossover arm.";not reported;;;;;128;https://doi.org/10.1002/14651858.CD012099.pub2;"Considering the rising prevalence of overweight and obesity globally and the known benefits of breastfeeding particularly in reducing the long?term risks of obesity and diabetes for infants; Mothers who do not breastfeed are at greater risk of female cancers and type 2 diabetes.";;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Hendra ;1990;EXCLUSION CRITERIA: pregnant, oral contraceptive pills;not reported;80 people (40 in each group, 56ñ1.3 years old) with type 2 diabetes;56;;;;;124;https://doi.org/10.1002/14651858.CD003641.pub4;Improvements for some aspects of health?related quality of life (QoL) (two RCTs) and diabetes (five RCTs) were also found;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Jain ;2002;"40 of the patients with type 2 diabetes (66% male) 
were randomized to 25 in the treatment group and 15 in the control arm";not reported;"65 people with type 2 diabetes (34 with vascular complications and 31 without) 
and 30 controls without type 2 diabetes. 40 of the patients with type 2 diabetes (66% male) were randomized to 25 in the treatment group and 15 in the control arm ( 52.3ñ8.8 years old and 5.41ñ4.31 years mean duration of diabetes)";52,3;;;;;156;https://doi.org/10.1002/14651858.CD002966.pub4;"Metformin monotherapy for type 2 diabetes mellitus

This review has been withdrawn";;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Luo ;1998;12 male participants;male;"12 male participants (54ñ9.5 years old) with 6ñ3.2 years of type 2 diabetes, 
not on insulin";54;;;;;116;https://doi.org/10.1002/14651858.CD007751.pub2;Angiotensin?converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non?diabetic chronic kidney disease;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;McGrath ;1996;23 participants (87% male) with type 2 diabetes;both;;not reported;;;;;109;https://doi.org/10.1002/14651858.CD007543.pub2;Objectives: To examine the evidence for enhanced glucose control in the prevention of distal symmetric polyneuropathy in people with type 1 and type 2 diabetes.;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;McManus ;1996;11 participants (73% male) ;both;"11 participants (61.8ñ9.6 years old, 73% male) 
with 7.7ñ6.9 years of well?controlled type 2 diabetes";61,8;;;;;64;https://doi.org/10.1002/14651858.CD009613.pub4;Randomised controlled trials (RCTs) and quasi?RCTs comparing techniques of blood glucose monitoring including SMBG, continuous glucose monitoring (CGM), automated telemedicine monitoring or clinic monitoring among pregnant women with pre?existing diabetes mellitus (type 1 or type 2).;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Morgan ;1995;40 participants (50% males);both;"40 participants (50% males, mean age 54 years with 7?10 years of diabetes) 
with hypertriglyceridemia and well?controlled type 2 diabetes. They were divided into 4 groups: 2 doses of fish oil and 2 doses of placebo (10 patients per group).";54;;;;;96;https://doi.org/10.1002/14651858.CD012202.pub2;Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Mostad ;2006;;not reported;"27 participants (13 in the fish oil arm, and 14 in the placeob arm, 55% male, 
aged 40 to 75 years)";not reported;;40-75;;;77;https://doi.org/10.1002/14651858.CD007610.pub3;types of participants: People aged 18 years or older with type 1 or type 2 diabetes mellitus in any healthcare setting. ;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Petersen ;2002;49 participants (62% male);both;"49 participants (62% male) with type 2 diabetes (20 in the treatment and 22 in the 
control arm in one publication and 23 in treatment and 21 in controls in another publication) with ñ 9.5 years duration of diabetes, aged 33 to 85 years.";not reported;;33-85;;;155;https://doi.org/10.1002/14651858.CD005102.pub3;"Dietary advice for the prevention of type 2 diabetes mellitus in adults

This review has been withdrawn";;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Puhakainen ;1995;9 community?dwelling participants (44% male);both;9 community?dwelling participants (44% male, 53ñ4 years old) with type 2 diabetes;53;;;;;51;https://doi.org/10.1002/14651858.CD008101.pub2;To assess the effects of CGM systems compared to conventional self?monitoring of blood glucose (SMBG) in patients with diabetes mellitus type 1.;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Schectman ;1988;13 participants (69% males);both;13 participants (69% males, 52ñ14.4 years old) with type 2 diabetes;52;;;;;10;https://doi.org/10.1002/14651858.CD012106.pub2;objectives: To assess the effects of SGLT 2 inhibitors focusing on the prevention or delay of T2DM and its associated complications in people with impaired glucose tolerance, impaired fasting blood glucose or moderately elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Silvis ;1990;32?46% male;both;"63 participants with type 2 diabetes (not well controlled (HbA1c 9?11), 32?46% male, 
Black, age 54ñ10 years) randomized to placebo (21, analyzed 18 in phase II), first fish oil then fiber (24, analyzed 21 in phase II) and first fiber then fish oil (18, analyzed 17 in phase II)";54;;;;;90;https://doi.org/10.1002/14651858.CD002181.pub2;selection criteria: Randomised controlled trials (RCTs) and before and after studies of the effects of a modified or restricted protein diet on diabetic renal function in people with type 1 or type 2 diabetes following diet for at least four months were considered.;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Sirtori ;1997; 62% male;both;"935 participants of whom 418 had type 2 diabetes divided into 211 for control and 
207 for fish oil (203 finished ? Intention to treat used); Control group: 58.8ñ8.9 years old, 62% male; Intervention: 58.2ñ9 years old, 62% male";;58,5;;;;44;https://doi.org/10.1002/14651858.CD012394.pub3;We searched the Cochrane Database of Systematic Reviews (6 August 2019) with key words ?gestational diabetes? OR ?GDM? to identify reviews pre?specifying GDM as an outcome;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Vessby ;1990;14 participants with type 2 diabetes (78% males);both;14 participants with type 2 diabetes (78% males, ages 39?72);;;39-72;;;;;;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Westerveld ;1993;24 participants (62.5% male);both;24 participants (62.5% male) with type 2 diabetes divided into three groups of 8;;;;;;;;;;;;;
35;https://doi.org/10.1002/14651858.CD003205.pub2;Omega?3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus;2008;22;Woodman ;2002;39 men and 12 women;both;"59 participants with type 2 diabetes, (39 men and 12 women; age 61.2ñ1.2 years; 
duration of diabetes 5.2ñ4.8 years). 17 were randomized to eicosapentaenoic acid, 18 to docosahexaenoic acid, and 16 in the placebo arm DROP?OUTS: 8";61,2;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Allie ;2004;Sex: NR;not reported;"Number: 23; Age: 53; Sex: NR";53;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Bach ;1999;;not reported;"Randomization procedure: NR; Allocation concealment: Unclear; Follow?up: 32w; 
Note: This study did not fit inclusion criteria as did not present weight outcomes, however it presented adverse event data among persons with diabetes, and is therefore presented here.";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Bandisode ;1975;Sex: 72%F;both;"Country: USA 
Setting: NR
Number: 64
Age: 50y 
Sex: 72%F
Medications: No insulinBL wt: 95BL BMI: NRBL GHb: NR";50;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Bloch ;2003;Sex: 83% ;both;"Country: Brazil
Setting: Hypertension clinic
Number: 204 total; 76 analyzed with diabetes
Age: 56 years
Sex: 83% 
overallMedications: I: 68% oral agents, 8% insulin; C: 63% oral agents and 18% insulinBL wt: I 91.5, C 87.5BL BMI: I 36.6, C 35.4BL GHb: NRNote: Demographic information was given only for whole study group (39% with diabetes), including persons with diabetes and those without.";56;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Bonnici ;2002;;not reported;"Country: South Africa
Setting: Multicenter trial; no details
Number: 284
Age: NR
Sex: NR
Medications: Metformin and/or sulfonylureaBL wt: NRBL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Boshell ;1974;;not reported;"Country: USA
Setting: NR
Number: 64
Age: NR
Sex: NR
Medications: None, diet only controlBL wt:BL BMI:BL GHb:";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Bratusch?Marrian;1979;Sex: 66%F;both;"Country: Austria
Setting: Unclear
Number: 40
Age: 50
Sex: 66%F
Medications: NR
BL wt: I 80.3, C 93.9BL BMI: I 30.8, C 41.7BL GHb: NR";50;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Buckle ;1966;Sex: 80%F;both;"Country: UK
Setting: Hospital diabetes clinic
Number: 22
Age: 58 from table 1
Sex: 80%F
Medications: NRBL wt: 78BL BMI: NRBL GHb: NR";58;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Campbell ;1977;;not reported;"Country: Scotland
Setting: Community clinic
Number: 66
Age: NR
Sex: NR
Medications: 12% insulin; 44% oral treatmentBL wt: NRBL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Chiasson ;1989;Sex: NR;not reported;"Country: Canada
Setting: NR
Number: 278
Age: 52y
Sex: NR
Medications: NRBL wt: 100.5BL BMI: 37BL GHb: I 7.4, C 7.3";52;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Connolly ;1995;Sex: 38%F;both;"Country: Scotland
Setting: Diabetic clinic
Number: 30
Age: 66
Sex: 38%F
Medications: Diet onlyBL wt: I 92.0, C 85.1BL BMI: I 32.0, C 31.5BL GHb: I 8.0, C 8.7";66;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Crommelin ;1974;Sex: Predominantly female;both;"Country: USA
Setting: Private practice
Number: 10
Age: Approximately 50
Sex: Predominantly female
Medications: NRBL wt: 85.0BL BMI: NRBL GHb: NR";50;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Daubresse ;1996;Sex: NR;not reported;"Country: Belgium
Setting: Community hospital clinic
Number: 82
Age: 52y
Sex: NR
Medications:BL wt: I 93, C 90.9 BL BMI: I 34.5, C 34.0BL GHb: I 8.5, C 8.6";52;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Deerochanawong ;2001;Sex: NR;not reported;"Country: NR
Setting: NR
Number: 252
Age: NR
Sex: NR
Medications: No insulin or acarboseBL wt: I 77, C 77BL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Dimitrov ;2001;Sex: NR;not reported;"Country: Bulgaria
Setting: Academic medical clinic
Number: 12
Age: NR
Sex: NR
Medications: NRBL wt: 103.6BL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Dolecek ;1976;Sex: 78%F;both;"Country: Czechoslovakia
Setting: NR
Number: 32
Age: 
Sex: 78%F
Medications: 38% oral agents, 31% insulinBL wt: 97.3BL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Felt ;1977;Sex: 83%F;both;"Country: Czechoslovakia
Setting: NR
Number: 24
Age: 47y
Sex: 83%F
Medications: 50% diet only, 50% oral agentBL wt:BL BMI:BL GHb:";47;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Finer ;2000;Sex: 53%;both;"Country: UK
Setting: Two hospital?based diabetes clinics
Number: 91
Age: 54
Sex: 53%
Medications: 14% diet only; 24% insulinBL wt: I 84.6, C 82.5BL BMI: I 30.6, C 31.0BL GHb: 9.5";54;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Fujioka ;2000;Sex: 41%F;both;"Country: USA
Setting: Multicenter; medical centers
Number: 175
Age: 54
Sex: 41%F
Medications: Sulfonurea, metformin or diet onlyBL wt: 99.3(1) 98.2 CBL BMI: 34.1(1) 33.8 CBL GHb: 8.4 (1) 8.3 C";54;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Gershberg ;1972;Sex: NR;not reported;"Country: USA
Setting: NR
Number: 12
Age: NR
Sex: NR
Medications: NRBL wt: ave 143% ideal body weightBL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Gershberg ;1977;Sex: 64%F;both;"Country: USA
Setting: Unclear
Number: 22
Age: NR
Sex: 64%F
Medications: No insulinBL wt: I 85.0, C 84.1BL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Gokcel ;2001;Sex: 100%F;female;"Country: Turkey
Setting: Academic medical cetner
Number: 60
Age: 48
Sex: 100%F
Medications: Sulfonurea and metforminBL wt: 95.6(1) 95.5¸BL BMI: 39.3(1) 37.4¸BL GHb: 10.0 (I) 9.8¸";48;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Goldstein ;1992;Sex: NR;not reported;"Country: USA
Setting: NR
Number: 278
Age: NR
Sex: NR
Medications: NRBL wt: 100BL BMI: NRBL GHb: I 7.4, C 7.2";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Gray ;1992;Sex: I 67% F, C 42% F;both;"Country: USA
Setting: Single, university clinic
Number: 48
Age: 55
Sex: I 67% F, C 42% F 
Medications: InsulinBL wt: I 106, C 107BL BMI: I 38, C 39.0BL GHb: I 10.5, C 10.2";55;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Griffiths ;1995;Sex: NR;not reported;"Country: USA
Setting: NR
Number: 83
Age: NR
Sex: NR
Medications: NRBL wt: NRBL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Guy?Grand;2001;Sex: NR;not reported;"Country: France
Setting: Multicenter, details NR
Number: 193
Age: 52
Sex: NR
Medications: Oral hypoglycemic agentsBL wt: NRBL BMI: 33.7BL GHb: 7.7";52;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Halpern ;2003;Sex: 69%F;both;"Country: Latin America
Setting: NR
Number: 338
Age: 51
Sex: 69%F
Medications: No insulin or acarboseBL wt: 89.6BL BMI: 34.6BL GHb: 8.4%";51;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Hanefeld ;2002;Sex: 56%F;both;"Country: Germany
Setting: Outpatient clinics
Number: 383
Age: 51y
Sex: 56%F
Medications: Diet or sulphonurea; no insulinBL wt: I 98.4, C 99.4BL BMI: I 33.7, C 34.5BL GHb: I 8.6, C 8.6";51;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Hawkins ;2000;Sex: NR;not reported;"Country: NR
Setting: Multicenter trial, details unclear
Number: 307
Age: NR
Sex: NR
Medications: NRBL wt: NRBL BMI: >27BL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Hendon ;1962;Sex: NR;not reported;"Country: USA
Setting: academic endocrine clinic
Number: 40
Age: 51y
Sex: NR
Medications: NoneBL wt: 85BL BMI: NRBL GHb: NR";51;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Hollander ;2001;Sex: NR;not reported;"Country: USA
Setting: NR
Number: 503
Age: NR
Sex: NR
Medications: MetforminBL wt: NRBL BMI: >28BL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Kaukua ;2004;Sex: 70%F (calculated weighted);both;"Country: Finland
Setting: Finnish primary medical care centers
Number: 236
Age: 54
Sex: 70%F (calculated weighted)
Medications: Diet only BL wt: I 100.8, C 98.1BL BMI: I 35.7, C 35.6 BL GHb: NR";54;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Kelley ;1997;Sex: NR;not reported;"Country: USA
Setting: Multicenter
Number: 322
Age: NR
Sex: NR
Medications: SulfonureasBL wt: NRBL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Kelley ;2002;Sex: 57%F;both;"Country: USA
Setting: Multicenter; academic medical centers
Number: 550
Age: 58
Sex: 57%F
Medications: Insulin +/? oral agent (excluding thazolidindiones)BL wt: I 101.8, C 102.0 BL BMI: I 35.6, C 35.8BL GHb: I 9.0, C 9.0";58;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Kelley ;2004;Sex: 67;both;"Country: USA
Setting: Academic center; community recruitment
Number: 39
Age: 51
Sex: 67
Medications: Oral agents or diet; oral agents withdrawn 1 month prior to interventionBL wt: I 99, C 102BL BMI: I 34.0, C 35.9BL GHb: I 8.1, C7.8";51;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Kutnowski ;1990;Sex: 66%F;both;"Country: Belgium
Setting: Multicenter, no details
Number: 134
Age: NR
Sex: 66%F
Medications: NR; NIDDM and IGT patients combinedBL wt: NRBL BMI: I 34.1, C 34.1 BL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Kutnowski ;1992;Sex: 47%F;both;"Country: Belgium
Setting: Multicenter; details Unclear
Number: 97
Age: 51
Sex: 47%F
Medications:BL wt: I 91.0, C 92.3BL BMI: I 34.4, C 34.3BL GHb: NR";51;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;le Roux;2001;Sex: NR;not reported;"Country: England
Setting: NR
Number: 7
Age: NR
Sex: NR
Medications: NRBL wt: NRBL BMI: 40.2BL GHb: 8.7";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Lindgarde ;2000;Sex: 64% (whole population);both;"Country: Sweden
Setting: 33 primary care centers
Number: 99
Age: 54y (whole population)
Sex: 64% (whole population)
Medications: NRBL wt: NR for diabetic populationBL BMI: NR for diabetic populationBL GHb: I 8.7, C 10.0";54;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Martin ;2001;Sex: 51%F;both;"Country: Northern Ireland
Setting: Obesity clinic
Number: 55
Age: NR
Sex: 51%F
Medications: NRBL wt: I: 102.8, C 101.1BL BMI: NRBL GHb: I 37.8, C 42";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;McNulty ;2003;Sex: 56%F;both;"Country: Multicenter: England, Canada, France, Belgium
Setting: NR
Number: 195
Age: 49
Sex: 56%F
Medications: MetforminBL wt: 103.3BL BMI: 36.3BL GHb: 9.6";49;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Mendoza?Guadarra;2000;Sex: 60%F;both;"Country: Mexico
Setting: obesity clinic
Number: 30
Age: 51
Sex: 60%F
Medications: NRBL wt: NRBL BMI: I 31.3, C 30.6BL GHb: NR";51;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Miles ;2002;Sex: 48%F;both;"Country: USA
Setting: Multicenter; Unclear
Number: 505
Age: 53y
Sex: 48%F
Medications: Metformin +/? sulfonureaBL wt: I 101.1, C 102.1BL BMI: I 35.2, C 35.6BL GHb: I 8.8, C 8.9";53;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Montenero ;1964;Sex: 65%F;both;"Country: Italy
Setting: NR
Number: 50
Age: 54
Sex: 65%F
Medications: 17% insulin; 67% oral agentsBL wt: I 97 , C 92 BL BMI: NRBL GHb: NR";54;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;O'Kane;1994;Sex: 68%F;both;"Country: United Kingdom
Setting: Diabetic clinic
Number: 19
Age: 57
Sex: 68%F
Medications: 37% diet only; 63% on oral agents; no insulinBL wt: I 97.5, C 97.8BL BMI: I 36.8, C 35.8BL GHb: I 9.7, C 9.2";57;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Peirce ;1999;Sex: NR;not reported;"Country: USA
Setting: NR
Number: 35
Age: 18?60y
Sex: NR
Medications: Diet onlyBL wt: NRBL BMI: 28?40BL GHb: NR";;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Redmon ;2003;Sex: 46%F;both;"Country: USA
Setting: Academic medical center
Number: 61
Age: 54
Sex: 46%F
Medications: No insulinBL wt: I 109.1, C 112.4 BL BMI: I 37.8, C 38.6 BL GHb: I 8.1, C 8.2";54;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Rissanen ;1999a;Sex: NR;not reported;"Country: Finland
Setting: NR
Number: 236
Age: 18?60y
Sex: NR
Medications: Diet onlyBL wt: NRBL BMI: >28BL GHb: NR";;;18-60;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Sanders ;1976;Sex: 80%F;both;"Country: Australia
Setting: NR
Number: 18
Age: 40?65
Sex: 80%F
Medications: 11% diet, 61% oral agents, 28% insulinBL wt: NRBL BMI: NRBL GHb: NR";;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Segal ;2000;Sex: NR;not reported;"Country: USA
Setting: NR
Number: 245
Age: NR
Sex: NR
Medications: Oral sulfonureasBL wt: NRBL BMI: NRBL GHb: NR";not reported;;18-60;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Serrano?Rios;2001;Sex: NR;not reported;"Country: Spain
Setting: Multicenter; no other details
Number: 237
Age: NR
Sex: NR
Medications: Sulfonureas and/or metforminBL wt: NRBL BMI: >27BL GHb: NR";not reported;;40-65;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Serrano?Rios;2002;Sex: 58%F;both;"Country: Europe
Setting: Multicenter
Number: 134
Age: 53.6
Sex: 58%F
Medications: Sulfonylurea BL wt: I 92.0, C 94.2 BL BMI: NR BL GHb: I 9.0, C 9.5";53,6;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Silverstone ;1966;Sex: 80%F;both;"Country: England
Number: 50
Age: 56
Sex: 80%F
Medications: 56% diet only; no insulinBL wt: I 84.4, C 89.4BL BMI: NRBL GHb: NR";56;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Sircar ;2001;Sex: 89%;both;"Country: India
Setting: Unclear
Number: 27
Age: 44.7
Sex: 89%
Medications: NRBL wt: 75.4BL BMI: 32.1BL GHb: 9.6";44,7;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Slama ;1978;Sex: 38%F;both;"Country: France
Setting: NR
Number: 46
Age: 48y
Sex: 38%F
Medications: Diet onlyBL wt: I 84.9, C 81.0BL BMI: NRBL GHb: NR";48;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Stoa?Birketvedt;1998;Sex: 33%F;both;"Country: Norway
Setting: Hospital clinic
Number: 62
Age: 48Y
Sex: 33%F
Medications: 49% on oral agentsBL wt: I 103.9, C 102.0BL BMI: I 33.8, C 34.0BL GHb: NR";48;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Tankova ;2003;Sex: 53.7 % female ;both;"Country: Bulgaria
Setting: Clinical Center of Endocrinology and Gerontology, Medical University?Sofia
Number: 95
Age: 45.8
Sex: 53.7 % female 
Medications: 70% oral agents, 30% dietBL wt: I 95.3, C 91.7 BL BMI: I 33.9, C 34.2 BL GHb: I 7.4, C 7.3";45,8;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Tong ;2002;Sex: 61%F;both;"Country: China
Setting: NR
Number: 27
Age: 36
Sex: 61%F
Medications: NRBL wt: 93.2BL BMI: 34.2BL GHb: 8.5";36;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Vargas ;1994;Sex: NR;not reported;"Country: USA
Setting: NR
Number: 18
Age: NR
Sex: NR
Medications: BRBL wt: NRBL BMI: NRBL GHb: NR";not reported;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Versari ;2000;Sex: 80%F;both;"Country: NR
Setting: NR
Number: 21
Age: 55y
Sex: 80%F
Medications: 48% on oral agentsBL wt: NRBL BMI: 36.3BL GHb: NR";55;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Wang ;2003;Sex: 47.6;both;"Country: China
Setting: Clinic
Number: 63
Age: 41
Sex: 47.6
Medications: 100% oral agentsBL wt: I 85.0, C 83.0BL BMI: I 30.0, C 31.0 BL GHb: I 8.3, C 8.2";41;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Williams ;1968;Sex: 89%F;both;"Country: England
Setting: Unclear
Number: 63
Age: 58
Sex: 89%F
Medications: NoneBL wt: NRBL BMI: NRBL GHb: NR";58;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Wise ;1989;Sex: 73%F;both;"Country: UK
Setting: NR
Number: 190
Age: 51y
Sex: 73%F
Medications: NRBL wt: 96BL BMI: 35BL GHb: 9.6";51;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Zaletel ;2002;Sex: 58;both;"Country: Slovenia
Setting: Unclear
Number: 31
Age: 54
Sex: 58
Medications: NRBL wt: NRBL BMI: 38.1BL GHb: NR";54;;;;;;;;;;;;
46;https://doi.org/10.1002/14651858.CD004096.pub2;Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus;2005;65;Zelissen ;1992;Sex: 60%F;both;"Country: The Netherlands
Setting: Single, hospital clinic
Number: 20
Age: 50
Sex: 60%F
Medications: None or oral agentBL wt: I 97, C 106 BL BMI: >=29BL GHb: I 9.6, C 9.1";50;;;;;;;;;;;;
73;https://doi.org/10.1002/14651858.CD008277.pub2;Blood pressure targets for hypertension in people with diabetes mellitus;2013;5;ABCD?2V;2006;;not reported;"129 type?2 diabetic participants, 40 to 81 years of age, with a systolic BP
 < 140 mmHg, a diastolic BP between 80 and 90 mmHg, and without evidence of overt albuminuria (< 200æg/min).";;;40-80;;;;;;;;;;
73;https://doi.org/10.1002/14651858.CD008277.pub2;Blood pressure targets for hypertension in people with diabetes mellitus;2013;5;ABCD?H;1998;;not reported;"472 participants, between the ages of 40 and 74 years, with type 2 diabetes mellitus
 and a diastolic blood pressure equal to or higher than 90 mm Hg were included.";;;40-74;;;;;;;;;;
73;https://doi.org/10.1002/14651858.CD008277.pub2;Blood pressure targets for hypertension in people with diabetes mellitus;2013;5;ABCD?N;2002;;not reported;"480 participants, aged 40 ? 74 years, with type 2 diabetes mellitus were included.
All of them had a baseline diastolic blood pressure between 80 and 89 mmHg and were not receiving antihypertensive medications at the randomization visit.";;;40-74;;;;;;;;;;
73;https://doi.org/10.1002/14651858.CD008277.pub2;Blood pressure targets for hypertension in people with diabetes mellitus;2013;5;ACCORD BP;2010;;not reported;"4733 participants were included in the ACCORD BP trial.ÿParticipants were eligible
if they had type 2 diabetes mellitus and a glycated hemoglobin level of 7.5% or more, and were 40 years of age or older with cardiovascular disease or 55 years of age or older with anatomical evidence of a substantial amount of atherosclerosis, albuminuria, left ventricular hypertrophy, or at least 2 additional risk factors for cardiovascular disease (dyslipidemia, hypertension, smoking, or obesity).ÿParticipants with a systolic blood pressure between 130 and 180 mmHg who were taking 3 or fewer antihypertensive medications and who had the equivalent of a 24?hour protein excretion rate of less than 1.0 g were also eligible for the blood pressure trial.";;;>40;;;;;;;;;;
73;https://doi.org/10.1002/14651858.CD008277.pub2;Blood pressure targets for hypertension in people with diabetes mellitus;2013;5;HOT ;1998;;not reported;"The entire study population was composed of 18,790 patients with elevated blood 
pressure, aged 50 ? 80 years. Of these, 1501 participants had diabetes at baseline and constitute the population included in this analysis.";;;50-80;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Berard ;2015;;not reported;"participant in the ACCORD trial from the Winnipeg ACCORD trial centre, receiving 
basal insulin therapy with a long?acting insulin analogue, ineligible for financial reimbursement for the drug (provincial or private) or unable to afford to pay for insulin glargine";not reported;;;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Bet“nico ;2019;;not reported;"type 2 diabetes mellitus; chronic kidney disease, stages 3 and 4 (glomerular 
filtration rate 15?59 mL/minute/1.73 mý) secondary to diabetic nephropathy, aged 40?80 years; use of basal bolus insulin ? 3 months before the study (NPH as basal insulin and regular insulin at meals)";;;40-80;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Eliaschewitz ;2006;men or women;both;"men or women; aged ? 75 years; BMI ? 35 kg/mý; type 2 diabetes mellitus and failed
 to achieve good metabolic control on OADs (HbA1c levels ? 7.5% and ? 10.5%; FBG ? 100 mg/dL; required to have been receiving OADs (any SUs, including glimepiride, or a combination of SUs with other OADs such as metformin or acarbose) for ? 6 months; previous doses of SUs were required to have been at least equivalent to glimepiride 3 mg; needed to be willing to follow a tight antidiabetic therapy; women of childbearing age needed to use an acceptable form of contraception";;;<75;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Fajardo Monta¤ana;2008;men or women;both;"men or women aged ? 18 years type 2 diabetes mellitus; overweight or obese ? 
BMI 25.0?40 kg/mý; HbA1c 7.5?11.0%; treated with 2 daily doses of insulin (? 1 of them a premix) for ? 3 months ñ metformin 1000?2550 mg daily";;;? 18;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Fritsche ;2003;;not reported;"type 2 diabetes mellitus, aged < 75 years; previous therapy
with SU as monotherapy or in combination with metformin or acarbose; BMI < 35 kg/mý; HbA1c 7.5?10.5%; FPG ? 6.7 mmol/L";;;<75;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Haak ;2005;exclusion criteria: pregnancy or breastfeeding;not reported;"type 2 diabetes mellitus ? 12 months, aged ? 35 years; insulin treatment for 
? 2 months (basal insulin dose ? 30% of the total daily insulin dose); HbA1c ? 12%";;;?35;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Hermanns ;2015;;not reported;"aged 18?80 years; type 2 diabetes mellitus; BMI > 22 kg/2ý to < 40 kg/mý; 
HbA1c 7.0?10.0%; FBG ? 6.7 mmol/L (120 mg/dL)";;;18-80;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Hermansen ;2006;insulin?naive people;not reported;"insulin?naive people; aged ? 18 years; BMI ? 35 kg/mý; HbA1c 7.5?10.0%; type 2 
diabetes mellitus for ? 12 months; inadequate control required ? 4 months treatment with 1 or 2 OADs at doses at least half the recommended maximum or highest tolerated";;;?18;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Home ;2015;;not reported;"insulin?naive; aged 30?70 years; type 2 diabetes mellitus diagnosed for > 1 year; 
HbA1c ? 7.0% and ? 10.5%; BMI < 40 kg/mý; treated with ? 1 OAD (metformin (daily dose ? 1000 mg), SU, glinides or alpha?glucosidase inhibitor) at stable dose for ? 3 months";;;30-70;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Hsia ;2011;;not reported;"insulin?naive other than previous use for gestational diabetes or for < 1 week during 
hospitalisation; aged 18?75 years; type 2 diabetes for ? 1 year; HbA1c: 7.5?12.0% despite ? 3 months of consistent therapy with maximally tolerated doses of combination of OADs (metformin, SUs, thiazolidinediones, or a combination); BMI 20?40 kg/mý";;;18-75;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Kawamori ;2003;exclusion criteria: pregnancy or breastfeeding;not reported;"type 2 diabetes mellitus, aged 20?70 years; previous therapy with OAD (SU 
monotherapy or in combination with ??glucosidase?inhibitors, metformin or ??glucosidase?inhibitors and metformin) for ? 12 weeks; BMI < 30 kg/mý; HbA1c > 8.0 to < 12.0%";;;20-70;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Kobayashi ;2007 A;;not reported;"people with diabetes (type 1 and type 2 diabetes); aged ? 20 years, HbA1c < 11%; 
BMI < 30.0 kg/mý, who had been receiving for ? 12 weeks basal?bolus therapy comprising the concomitant use of intermediate? or long?acting human insulin preparation once a day before bedtime, or twice a day, before breakfast and before bedtime, and insulin aspart 3 times a day immediately before every meal

[selction criteria: We included randomised controlled trials (RCTs) comparing the effects of treatment with (ultra?)long?acting insulin analogues to NPH in adults with type 2 diabetes mellitus.]";;;?20;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Kobayashi ;2007 B;;not reported;"people with insulin?naive type 2 diabetes; aged ? 20 years, HbA1c ? 7.5% 
but < 10.0%; BMI < 30.0 kg/mý, who had been receiving for ? 12 weeks oral diabetes drug therapy (SU agent, SU agent + biguanide agent, SU agent + ??glucosidase inhibitor (hereafter, ??glucosidase inhibitor) or SU agent + biguanide agent + ??glucosidase inhibitor)";;;?20;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Massi ;2003;;not reported;"diabetes duration ? 3 years; aged 40?80 years; oral therapy with SUs alone or in 
combination with acarbose, metformin, or metformin alone, or insulin once daily + OADs for ? 1 year; BMI < 40 kg/mý; HbA1c > 7.5% to < 12.0%; negative history of ketoacidosis";;;40-80;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;NCT00687453;;"female of childbearing potential without reliable form of 
contraception; current pregnancy or lactation";not reported;"type 2 diabetes mellitus for ? 1 year; HbA1c ? 7.5% and < 12% on stable and 
maximum?tolerated doses of a SU, metformin, thiazolidinedione + a single bedtime injection of NPH insulin; mean FPG < 130 mg/dL without fasting hypoglycaemia; except for current NPH insulin no other history of chronic insulin use (other than treatment of gestational diabetes or hospitalisation of < 1 week' duration); BMI 20?40 kg/mý; aged 18?75 years";;;18-75;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;NN304?1337 ;;people with type 2 diabetes;not reported;"people with type 2 diabetes ? 1 year; aged ? 35 years; treatment with metformin 
(> 1000 mg/day) alone or in combination with other OADs; HbA1c ? 8.0% to ? 10.0% if pretreated with ? 3 OADs or HbA1c ? 8.0% to ? 12.0% if pretreated with < 2 OADs; BMI ? 40 kg/mý";;;?35;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;NN304?1808 ;;;not reported;"type 2 diabetes; aged ? 70 years; insulin naive and treated with OADs at the 
maximum tolerated dose for ? 3 months and not achieving therapeutic targets (HbA1c 7.0?8.0%); 8.0% ? HbA1c ? 10.5% (local dosage within last 6 months); able to comply with the requirements of the trial";;;?70;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;NN304?3614 ;;people with type 2 diabetes;not reported;"people with type 2 diabetes; treated with 2 or 3 doses of insulin for ? 3 months prior 
to inclusion; aged ? 18 years; BMI ? 27.5 kg/mý and ? 40 kg/mý; HbA1c ? 7% to ? 11.0% centrally measured";;;?18;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Pan ;2007;"insulin?naive people from Asia
exclusion criteria: pregnancy";not reported;"insulin?naive people from Asia aged ? 40 and ? 80 years with type 2 diabetes poorly 
controlled on OHA therapy (SU alone or in combination with metformin or acarbose) for ? 3 months prior to study entry (previous doses of SUs were equal to or greater than equivalent doses of glimepiride 3 mg) + a random venous plasma glucose concentration ? 11.1 mmol/L or FPG concentration ? 7 mmol/mol or 2?hour plasma glucose concentration ? 11.1 mmol/L in an oral glucose tolerance test (glucose 75 g); BMI 20?35 kg/mý; HbA1c: ? 7.5% and ? 10.5%; FBG levels > 120 mg/dL (> 6.7 mmol/L)";;;40-80;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Riddle ;2003;people with type 2 diabetes;not reported;"people with type 2 diabetes for ? 2 years; aged 30?70 years; stable dose of 1 or 2 
oral antihyperglycaemic agents (SUs, metformin, glitazone) for ? 3 months; BMI 26?40 kg/mý; HbA1c ? 7.5% to ? 10.0%; FPG ? 7.8 mmol/L";;;30-70;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Rosenstock ;2001;people with type 2 diabetes;not reported;"people with type 2 diabetes; aged 40?80 years; insulin treatment for ? 3 months; 
BMI < 40 kg/mý; HbA1c ? 7.0% to ? 12.0%";;;40-80;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Rosenstock ;2009;;not reported;"aged 30?70 years; diagnosis of type 2 diabetes mellitus for ? 1 year; treated with
OHAs or insulin alone or a combination of OADs and insulin for ? 1 year prior to screening, with a stable dose(s) for ? 3 months prior to screening; HbA1c 6.0?12.0% at screening; baseline retinopathy severity not to exceed 53/<53 on the ETDRS scale; unlikely to require laser surgery or vitrectomy within upcoming year";;;30-70;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Yki?J„rvinen;2006;men or women;both;"men or women; aged 35?75 years; type 2 diabetes mellitus; had been treated with 
a stable dose of SU (any dose) and metformin (? 1.5 g) or with metformin alone for ? 3 months; BMI 20?40 kg/mý; HbA1c ? 8.0%; mean FPG ? 7 mmol/L (daily home glucose monitoring); fasting C?peptide ? 0.33 nmol/L (reference range 0.33?0.69 nmol/L)";;;35-75;;;;;;;;;;
26;https://doi.org/10.1002/14651858.CD005613.pub4;(Ultra?)long?acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus;2020;24;Yokoyama ;2006;;not reported;"type 2 diabetes mellitus; 2 years' duration of diabetes mellitus; aged ? 35 years; 
negative GAD test; without any episodes of ketoacidosis; BMI ? 40 kg/mý; HbA1c ? 10%; people had once had poor glycaemic control (HbA1c ? 8%) despite optimal dose of SUs in addition to diet and exercise; for > 1 year on basal/prandial insulin therapy using aspart/lispro at each meal and NPH at bedtime with or without any antidiabetic oral agents";;;?35;;;;;;;;;;
15;https://doi.org/10.1002/14651858.CD003804.pub2;Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia;2017;7;Abbatecola ;2006;"Sex: glibenclamide (glyburide) group = 41 female/38 male
repaglinide group = 39 female/38 male.";both;"156 older people with Type 2 diabetes (age range 60 to 78 years) volunteered for the 
study. Participants were selected from a group of approximately 250 individuals with diagnosed Type 2 diabetes from university outpatient offices. Physicians were asked to refer older persons with Type 2 diabetes who had not previously undergone any antidiabetic drug treatment to their offices where further selection was performed.

Total number randomised: 156. 
Age: glibenclamide (glyburide) group = 74.3 (SD 2.3) years; repaglinide group = 74.5 (SD 2.5) years";74,4;74,4;60-78;;;;;;;;;;
15;https://doi.org/10.1002/14651858.CD003804.pub2;Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia;2017;7;ADVANCE ;2008;"Sex (female): intervention group = 42.6%
standard group = 42.3%.";both;"diagnosis of Type 2 diabetes mellitus at 30 years of age or older, an age of at least 
55 years at the time of study entry, and a history of major macrovascular or microvascular disease or at least one other risk factor for vascular disease.

Age: intervention group = 66 (SD 6); standard group = 66 (SD 6). ";66;66;55;;;;;;;;;;
15;https://doi.org/10.1002/14651858.CD003804.pub2;Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia;2017;7;Araki ;2012;"Sex (female): intervention group = 53.7%
control group = 53.7%.";both;"inclusion criteria included age 65 to 85 years, HbA1c ? 7.9% or HbA1c ? 7.4% with 
at least one of following criteria: BMI ? 25 kg/m2, blood pressure ? 130/85 mmHg, serum total cholesterol ? 200 mg/dL (or low?density lipoprotein cholesterol (LDL?C) ? 120 mg/dL in participants without coronary heart disease (CHD)) or ? 180 mg/dL (or LDL?C ? 100 mg/dL in participants with CHD), triglycerides ? 150 mg/dL and HDL?C < 40 mg/dL.

Total number randomised: 585 participants to the intervention group and 588 in the control group
Age: intervention group = 71.9 (SD 4.6); control group = 71.7 (SD 7.7). ";71,8;71,8;65-85;;;;;;;;;;
15;https://doi.org/10.1002/14651858.CD003804.pub2;Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia;2017;7;Guo ;2014;"Sex (male/female): intervention group = 17/12
control group = 19/10.";;"participants with depression diagnosed according to the Diagnostic and Statistical 
Manual of Mental Disorders?Fourth Edition (DSM?IV) and a Type 2 diabetes newly diagnosed by laboratory.

intervention group = 17/12; control group = 19/10
Age: intervention group = 54.7 (SD 7.3); control group = 53.3 (SD 7.3)";54;54;;;;;;;;;;;
15;https://doi.org/10.1002/14651858.CD003804.pub2;Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia;2017;7;Launer ;2011;"Sex (female): intervention group = 48%
control group = 49%.";both;"participants targeted by ACCORD MIND, which was done in 77 clinics in North 
America, were aged 45 to 79 years and had Type 2 diabetes, high HbA1c concentrations (> 7.5%, > 58 mmol/mol), and a high risk for cardiovascular disease events suggested by significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two additional risk factors for cardiovascular disease.

1469 participants to the intervention group and 1508 in the control group (2794 analysed). 
Age: intervention group = 62.3 (SD 5.7); control group = 62.7 (SD 5.9). ";62,5;62,5;45-79;;;;;;;;;;
15;https://doi.org/10.1002/14651858.CD003804.pub2;Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia;2017;7;Ryan ;2006;"Sex (female): rosiglitazone plus metformin group = 43%
glibenclamide (glyburide) plus metformin group = 36% female";both;"145 adults with Type 2 diabetes were recruited from 18 centres in the US. Adults 
were eligible if they were receiving oral metformin combination therapy and had HbA1c (A1C) ? 8%, BMI ? 27 kg/m2, no evidence of dementia (score ? 27 on the Mini?Mental State Examination), and no evidence of current depression as determined by the Mini International Neuropsychiatric Interview (MINI).

Age: rosiglitazone plus metformin group = 60.7 (SD 1.0 years); glibenclamide (glyburide) plus metformin group = 59.6 (SD 0.8 years)";60,15;;;;;;;;;;;;
15;https://doi.org/10.1002/14651858.CD003804.pub2;Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia;2017;7;Zimering ;2016;"Sex (female): intensive group = 53.7%
standard group = 53.7%.";both;"The participants were recruited from 20 participating Veteran Affairs Medical Centers 
in the USA. Inclusion criteria included > 41 years old, who are non?responsive to a maximum dose of at least one oral agent and/or daily insulin injections. Non?responsiveness is defined as having centrally measured HbA1c level > 4 standard deviations above the normal mean, that is, > 7.5%, or else local HbA1c > 8.3%.

Total number randomised: 892 participants to the intensive group and 899 in the standard group
Age: intensive group = 60.5 (SD 9.0); standard group = 60.3 (SD 9.0). ";60,4;60,4;>41;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Hanefeld ;1991;Sex: 43%F;both;"Follow?up: 260w No. study arms: one Setting: Germany, diabetes clinic Number: 1139 Comparison: Usual care 

Age: 47y Sex: 43%F Duration DM: NR Treatment: Diet only BL wt, BMI: NR, 28.9 
BL GHb: NR";47;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Heitzmann ;1987; Sex: 52%F;both;"Follow?up: 78w No. study arms: Three Setting: USA, setting unclear Number: 44 Comparison: Muscle relaxation 

Age: 53y Sex: 52%F Duration DM: NR Treatment: 60% insulin or oral agents 
BL wt, BMI: 81.7, NR BL GHb: 10.7";53;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Heller ;1988;Sex: 45%F;both;"Follow?up: 52w No. study arms: Two Setting: UK, University Hospital Number: 87 Comparison: Usual care 

Age: 56y Sex: 45%F Duration DM: NR Treatment: Diet only BL wt, BMI: 86.1, 32.0 
BL GHb: 12.7";56;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Hockaday ;1978;Sex: 44%F;both;"Follow?up: 52w No. study arms: Two Setting: UK, diabetes clinic Number: 93 Comparison: Low CHO, calorie restricted diet 

Age: 52y Sex: 44%F Duration DM: NR Treatment: Diet only BL wt, BMI: 76.4, NR 
BL GHb: NR";52;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Kaplan 1987 (D+PA) ;1987;Sex: 58%F;both;"Follow?up: 78w No. study arms: Three Setting: intervention groups (diet, PA, diet + PA) USA; setting unclear Number: 76 Study design: Quasi?randomized trial Comparison: Weekly didactic presentations on general diabetes care 

Age: 55y Sex: 58%F Duration DM: NR Treatment: 37% diet only, 25% insulin 
BL wt, BMI: 92.2, NR BL GHb: 8.2";55;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Kaplan 1987 (diet) ;1987;Sex: 58%F ;both;"Follow?up: 78w No. study arms: Three Setting: intervention groups (diet, PA, diet + PA) USA; setting unclear Number: 76 Study design: Quasi?randomized trial Comparison: Weekly didactic presentations on general diabetes care 

Age: 55y Sex: 58%F Duration DM: NR Treatment: 37% diet only, 25% insulin 
BL wt, BMI: 92.2, NR BL GHb: 8.2";55;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Kaplan 1987 (PA) ;1987;Sex: 58%F;both;"Follow?up: 78w No. study arms: Three Setting: intervention groups (diet, PA, diet + PA) USA; setting unclear Number: 76 Study design: Quasi?randomized trial Comparison: Weekly didactic presentations on general diabetes care 

Age: 55y Sex: 58%F Duration DM: NR Treatment: 37% diet only, 25% insulin 
BL wt, BMI: 92.2, NR BL GHb: 8.2";55;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Korhonen ;1987;Sex: 48%F;both;"Follow?up: 52w No. study arms: Two Setting: Finland, university clinic Number: 71 Comparison: Written materials from doctor at first visit 

Age: 56y Sex: 48%F Duration DM: NR Treatment: Diet only BL wt, BMI: 89.7, 32.2 
BL GHb: 10.9";56;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Metz ;2000;Sex: 58%F;both;"Follow?up: 52w No. study arms: Two Setting: USA, multicenter academic centers Number: 119 Comparison: Same diet, self?selected foods 

Age: 54y Sex: 58%F Duration DM: NR Treatment: No insulin 
BL wt, BMI: NR, 34.5 BL GHb: 8.8";54;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Milne ;1994;Sex: 55%F;both;"Follow?up: up to 78w, average 52w No. study arms: Two Setting: New Zealand, community hospital Number: 64 Comparison: 500kcal/d deficit diet 

Age: 59y Sex: 55%F Duration DM: 4.8y Treatment: Diet or oral agents 
BL wt, BMI: 78.3, 29.0 BL GHb: 9.0";59;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Muchmore ;2000;Sex: 61%F;both;"Follow?up: 52w No. study arms: Two Setting: USA, large group practice Number: 23 Comparison: Identical amount of attention; focused on ADA guidelines of general nutrition principles 

Age: 59y Sex: 61%F Duration DM: 5.5y Treatment: 26% diet only; 76 % oral agents 
BL wt, BMI: 99.1, 33.3 BL GHb: 10.5";59;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Pascale ;1995;Sex: 100%F;female;"Age: 56y Sex: 100%F Duration DM: NR Treatment: No insulin BL wt, BMI: 93.1, 36.4 
BL GHb: 10.9";56;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Pissarek ;1980;Sex: 60%F;both;"Age: 51y Sex: 60%F Duration DM: NR Treatment: No insulin, 53% diet only 
BL wt, BMI: 82.8, NR BL GHb: NR";51;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Sone ;2002;Sex: 45%F;both;"Follow?up: 156w No. study arms: Two Setting: Japan, multicenter, diabetes Clinics Number: 2205 Comparison: Usual care 

Age: 59y Sex: 45%F Duration DM: 11.3y Treatment: 21% diet only, 20% insulin 
BL wt, BMI: NR, 23.0 BL GHb: 7.8";59;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Trento ;1998;Sex: 46%F;both;"Follow?up: 52, 108 and 225w; No. study arms: Two; Setting: Italy, academic center; Number: 112; Comparison: Usual one?on?one clinic visits q3m

Age: 62y; Sex: 46%F; Duration DM: 9.6y; Treatment: 14% diet only, 86% oral agents; 
BL wt, BMI: 77.8, 27.9; BL GHb: 7.4";62;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Uusitupa ;1993;Sex: 43%F;both;"Follow?up: 52 and 104w No. study arms: Two Setting: Finland, academic diabetes center Number: 86 Comparison: Usual care in community clinic q3m 

Age: 53y Sex: 43%F Duration DM: 2y Treatment: Diet only 
BL wt, BMI: 88.8, 31.6 BL GHb: 7.8";53;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing 1988b ;1998;Sex: 65%F;both;"Follow?up: 68w No. study arms: Setting: USA, academic center Number: 20 Comparison: Same education; SMBG but no goals or teaching on how to adjust intake and activity 

Age: 53y Sex: 65%F Duration DM: NR Treatment: 20% diet only, 80% oral agents 
BL wt, BMI: 90.5, NR BL GHb: 10.5";53;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing 1985 (BM) ;1985;Sex: 62%F;both;"Follow?up: 68w No. study arms: Three Setting: groups: behavioral modification, nutrition education; usual care USA, academic center Number: 53 Comparison: Standard care, monthly meetings 

Age: 55y Sex: 62%F Duration DM: 5.9y Treatment: 25% diet only; 75% oral agents 
BL wt, BMI: 96.4, 34.8 BL GHb: 9.3";55;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing 1985 (NE) ;1985;Sex: 62%F;both;"Follow?up: 68w No. study arms: Three Setting: groups: behavioral modification, nutrition education; usual care USA, academic center Number: 53 Comparison: Standard care, monthly meetings 

Age: 55y Sex: 62%F Duration DM: 5.9y Treatment: 25% diet only; 75% oral agents 
BL wt, BMI: 96.4, 34.8 BL GHb: 9.3";55;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing ;1986;Sex: 78%F;both;"Follow?up: 62w No. study arms: Two Setting: USA academic center Number: 50 Comparison: 1000kcal/d diet with 20 visits 

Age: 54y Sex: 78%F Duration DM: NR Treatment: 50% oral agents, 50% insulin 
BL wt, BMI: 96.4, NR BL GHb: 10.9";54;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing 1988a (Study 1) ;1988;Sex: 84%F;both;"Follow?up: 62w No. study arms: Two Setting: USA, setting NR Number: 25 Comparison: Same diet and behavioral interventions; light calisthetics and flexibility exercises 

Age: 54y Sex: 84%F Duration DM: 4.6y Treatment: 52% diet, 48% oral agents 
BL wt, BMI: 98.9, 37.5 BL GHb: 9.6";54;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing 1988a (Study 2) ;1988;Sex: 70%F;both;"Follow?up: 62w No. study arms: Two Setting: USA, setting NR Number: 30

Age: 56y Sex: 70%F Duration DM: 7.0y Treatment: 27% insulin, 63% oral agents 
BL wt, BMI: 102, 37.9 BL GHb: 10.9";56;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing 1991a ;1991;Sex: 76%F;both;"Follow?up: 72w No. study arms: Two Setting: USA academic center Number: 36 Comparison: LCD 4200?6300J/d 

Age: 51y Sex: 76%F Duration DM: 7.0y Treatment: 18% diet only, 21% using insulin 
BL wt, BMI: 104.5, 38.1 BL GHb: 10.4";51;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing 1991b ;1991;Sex: 58%F;both;"Follow?up: 72w No. study arms: Two Setting: USA, setting unclear Number: 49 Comparison: No spouse attending meetings 

Age: 52y Sex: 58%F Duration DM: NR Treatment: 26% diet only, 21% insulin 
BL wt, BMI: 102.4, 35.7 BL GHb: 10.3";52;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing ;1994;Sex: 65%F;both;"Follow?up: 52 and 104w No. study arms: Two Setting: USA, academic medical center Number: 93 Comparison: 1000?1200kcal/d, weekly meetings 

Age: 52y Sex: 65%F Duration DM: 6.8y Treatment: 25% on insulin; stopped at beginning of study 
BL wt, BMI: 107.7, 38.3 BL GHb: 10.5";52;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Wing ;1995;Sex: 68%F;both;"Follow?up: 52w No. study arms: Two Setting: USA, community recruitment, setting unclear Number: 93 Comparison: 1000?1200 kcal/d, low fat 

Age: 51.8y Sex: 68%F Duration DM: 6.8y Treatment: 23% insulin, 60% oral agents 
BL wt, BMI: 106.8, 37.9 BL GHb: NR";51,8;;;;;;;;;;;;
25;https://doi.org/10.1002/14651858.CD004095.pub2;Long?term non?pharmacological weight loss interventions for adults with type 2 diabetes mellitus;2005;27;Zapotoczky ;2001;Sex: 68%F;both;"Follow?up: 52w No. study arms: Two Setting: Austria, academic internal medicine clinic Number: 36 

Age: 58y Sex: 68%F Duration DM: NR Treatment: 56% diet only, 44% oral agents 
BL wt, BMI: 82.3, NR BL GHb: 8.0";58;;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Bradshaw ;1999;Sex: M 52.2 %;both;"? 230 type 2 diabetes patients
? United Kingdom
? Urban
? Recruitement in primary care services
? Traditional (87), Video (86), Educator (57)
? Sex: M 52.2 %
? Age: mean 66.4, traditional (M: 66.7%), video (M: 46.8%), educator (M: 58.5%)
? Smoking: 22.2 %, traditional 28.7 %, video 23.3 %, educator 10.5%
? Weight: mean 77.9 kg
? HbA1c: mean 7.35, traditional 7.63, video 7.35, educator 6.91";66,4;;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Canga ;2000;Sex: intervention (F: 22, M: 125), control (F: 18, M: 115);both;"? 280 type 2 diabetes patients in outpatient settings in an urban area in Spain
? Multicentre study
? Sex: intervention (F: 22, M: 125), control (F: 18, M: 115)
? Age: intervention (54.4 +? 15), control (55.8 +? 14.9)
? Daily cigarettes: intervention (19.9 +? 11.9), control (19.8 +? 11.5)
? Years of smoking: intervention (36.4 +? 16), control (38 +? 15.2)
? BMI: intervention (27.0 +? 4.7), control (26.2 +? 4.4)
? treatment modality: insulin (intervention 47, control 47)";55,1;55,065;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Clarke ;2002;Sex: F: 386, M: 362;both;"? 748 type 2 diabetes patients ? Multicentre study, patients recruited in primary care services
? Sex: F: 386, M: 362
? Age: mean 59";59;;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Coast?Senior;1998;Sex: M: 23;male;"? 23 type 2 diabetes patients
? Single centre study in an urban area in the USA
? Patients recruited in primary care services
? Sex: M: 23
? Mean age: 65, SD 9.4
? HbA1c: 11.1%, SD 1.6
? Fasting blood glucose: 219 mg/dL 219, SD 45 mg/dl
? Random blood glucose: 236 mg/dl, SD 72 mg/dl
? Duration since diagnosis: 8.8 years, SD 4.2
? Treatment modality: diet + oral hypoglycaemic agents + insulin: 23";65;;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Davidson ;2000;Sex: intervention (F: 42, M: 47), control (F: 46, M: 46);both;"? Single centre study in primary care services in the USA
? Particpants: 181 type 2 diabetes patients (intervention: 89, control: 92)
? Sex: intervention (F: 42, M: 47), control (F: 46, M: 46)
? Mean age: intervention (54.8 years), control (51.8 years)
? Ethnicity: intervention (Afro?American 14.6%, Caucasian 14.6%, Hispanic 69.7%), control (Afro?American 17.4%, Caucasian 15.2%, Hispanic 64.1%, other 2.2%, undetermined 1.1%)
? Hypertension: intervention (67.4%), control (45.6%)
? HbA1c: intervention (8.8% (0.2) n=79), control (7.9 % (0.2), n=73)
? Retinopathy: intervention (n=29), control (n=14)
? Neuropathy: intervention (n=21), control (n=8)
? Nephropathy: intervention (n=35), control (n=13)
? Diabetic foot: intervention (n=15), control (n=1)
? Macrovascular complications (coronary artery disease or cerebrovascular disease): intervention (n=5), control (n=8)
? Treatment modality: diet alone (intervention 0, control 8), oral hypoglycaemic agents (intervention: 38, control: 51), insulin: (intervention: 20, control: 19), diet+oral agents+insulin: (intervention: 31, control 14)";53,3;53,275;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Diehl ;1985;Sex: intervention (F: 29, M: 11), control (F: 26, M: 11);both;"? Single centre study in the USA
? 77 type 2 diabetes patients recruited in outpatient settings
? Participants: intervention (chlorpropamide 40), control (insulin 37)
? Sex: intervention (F: 29, M: 11), control (F: 26, M: 11)
? Age: intervention (50.6 yrs, SD 9.5), control (51.2 yrs, SD 9.3)
? Ethnicity: intervention (95% Mexican?American), control (91.9% Mexican?American)
? Glycaemia: intervention (236.3 mg/dl, SD 81.5), control (243.6 mg/dl, SD 73.3)
? Treatment modality (prior to study): diet alone: intervention (40), control (37)";50,9;50,889;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Hopper ;1984;Sex: intervention (F: 83, M: 31), control (F: 84, M: 29);both;"? 227 type 2 diabetes patients
? Participants: intervention (114), control (113)
 ? Outpatients in a city in the USA
? Sex: intervention (F: 83, M: 31), control (F: 84, M: 29)
? Mean age: intervention (59), control (57)
? Ethnicity: intervention (Black 90), control (Black 79)
? Blood glucose: intervention (226 95%CI 214?238), control (221 95% CI 209?233)
? Duration since diagnosis: intervention (11 years), control (12)
? Treatment modality: oral hypoglycaemic agents: intervention (19%), control (23%)
? Treatment with insulin: intervention (81%), control (77%)";58;58,004;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Jaber ;1996; Sex: intervention (F: 12, M: 5), control (F: 15, M: 7);both;"Single centre study in a city in the USA
? Outpatients
? 39 type 2 diabetes patients (intervention 17, control 22)
? Sex: intervention (F: 12, M: 5), control (F: 15, M: 7)
? Mean age: intervention (59, SD 12), control (65, SD 12)
? Ethnicity: intervention and control groups: 100% African American
? Mean weight: intervention (93 kg, SD 22), control (88 kg, SD 19)
? BMI: intervention (34, SD 7), control (33, SD 7)
? BMI > 27: intervention (13), control (18)
? Systolic blood pressure: intervention (140 mmHg, SD 20), control (143, SD 23)
? Diastolic blood pressure: intervention (82, SD 10), control (88, SD 9)
? Hypertension: intervention (14), control (17)
? Lipid abnormalities: intervention (10), control (11)
? HbA1c: intervention (11.5%, SD 2.9), control (12.2%, SD 3.5)
? Fasting blood glucose: intervention (11.1 mmol/l, SD 4), control (12.7 mmol/l, SD 4.7)
? Duration since diagnosis: intervention (6.8 years, SD 6.5), control (6.2 yrs, SD 4.8)
? Treatment modality: diet + oral hypoglycaemic agents: intervention (17), control (22)
? Exclusion criteria: IDDM, renal dysfunction, history of non?attendance ";62;62,385;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Jiang ;1999;Sex: intervention (F 61, M 69), control (F 49, M 38);both;"? Multicenter study in urban areas in Taiwan. ? 217 type 2 diabetes patients in an outpatient setting.
? Inclusion criteria: aged between 35 and 70 years old, able to read, HbA1c level >/=8.0% and with stable metabolic control.
? Sex: intervention (F 61, M 69), control (F 49, M 38)
? Age: intervention (52.3 +? 6.7), control (52.9 +? 7.4)
? Body Mass Index: intervention (25.2 +? 3.5), contol (25.6 +? 3.2)
? Duration of disease since diagnosis: intervention (8.0 years +? 8.0), control 6.7 yrs +? 5.3)
? Treatment: Diet and oral hypoglycaemic agents: intervention 121, control 87 ";53,1;53,14;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Krier ;1999;Sex: intervention (F: 9, M: 5), control (F: 10, M: 4).;both;"? 39 type 2 diabetes patients living in a city in the United States.
? 21 people were allocated to the intervention group and 18 to the control group.
? Sex: intervention (F: 9, M: 5), control (F: 10, M: 4).
? Age: intervention (54.2 +? SD 5.6), control (56.2 +? SD 9).
? Ethnicity: intervention (6 Afro Americans), control (7 Afro Americans).
? Smoking: intervention (3), control (3).
? Weight: intervention (97.4 kg +? 23.9), control (93.8 +? 19.4).
? Locus of control: intervention (4.5 +?1), control (4.0 +? 1.1).
? Knowledge test: intervention (11.3 +? 3.8), control (14.2 +? 3.6).
? HbA1c: intervention (9.6% +? 1.9), control (10.3% +? 2.3).
? Treatment modality: oral hypoglycemic agents (intervention 8, control 7), insulin (intervention 5, control 5), combination (intervention 1, control 2). ";55,2;55,2;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Matsuyama ;1993;Sex: intervention (M: 15), control (F: 1, M: 16);both;"? 32 type 2 diabetes outpatients (USA veterans)
? Single centre study in an urban area in the USA
? Participants: intervention: 15, control: 17
? Sex: intervention (M: 15), control (F: 1, M: 16)
? Age: intervention (mean 64 years, SD 7), control (mean 64 yrs, SD 8)
? HbA1c: intervention (12.7%, SD 1.9), control (12.1 %, SD 2.6)
? Glycaemia: intervention (12.1 mmol/l, SD 1.9; 167.81 mg/dl, SD 35.57 ), control 11.1 mmol/l, SD 2.9; 147.63 mg/dl, SD 38.57)
? Duration since diagnosis: intervention (6.7 years, SD 7.6 yrs), control (8.5 years, SD 8.5 yrs)
? Treatment modality: oral hypoglycaemic agents: intervention 15, control 16 ";64;64;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Mease ;2000;;not reported;"? Single centre study in the USA
? 28 Type 2 diabetes patients recruited in primary care services
? Inclusion: HbA1c >8.0% ";not reported;;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Paes ;1997;Sex: F 59.6%;both;"? 91 type 2 diabetes patients
? Multicentre study in an urban area in the Netherlands
? Patients recruited in general practice
? Sex: F 59.6%
? Age: F 70.1 +? 10.7, M: 67.8 +? 11.2
? Treatment modality: oral hypoglycaemic agents ";70,1;69,105;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Piette ;2001;sex: intervention (M: 126), control (M: 138);both;"? Type 2 diabetes patients recruited in an outpatient setting in a mixed rural and urban area.
? Participants: intervention (132), control (140)
? sex: intervention (M: 126), control (M: 138)
? mean age: intervention (60 yrs, SD 10), control (61 yrs, SD 10)
? ethnicity: inter vention (Black: 32, Hispanic 18, Other 11), control (Black 17, Hispanic 16, Other 15)
? BMI: intervention (31, SD 7), control (31, SD 6)
? HbA1c: intervention (8.2%, SD 1.7), control (8.1, SD 1.7)
? serum glucose: intervention (188 mg/dl, SD 94), control (168 mg/dl, SD 68)
? all complications: intervention (1), control (0.7)
? vascular symptoms: intervention (0.7, SD 0.8), control (0.6, SD 0.8)
? treatment modality: insulin: intervention (39), control (31) ";60,5;60,515;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Pullar ;1988;;not reported;"? 179 type 2 diabetes outpatients
? Single centre study in a city in the UK.
? Age: group 1 (64.9 years +? 8.6), group 2 (63.5 years +? 10.5), group 3 (63.6 years +? 10.1)
? Treatment modality: all patients on diet and oral hypoglycaemic agents";64,2;;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Rachmani ;2002;Sex: intervention (F: 35, M: 36), control (F: 37, M: 33);both;"?Single centre study in Israel
? Not clear whehter the patients were recruted in a rural or an urban area.
? 142 type 2 diabetes patients: intervention (71), control (70)
? Sex: intervention (F: 35, M: 36), control (F: 37, M: 33)
? Mean age: intervention (57.4 years), control (56.8 years)
? BMI: intervention (28.4), control (28.7)
? Systolic blood pressure: internvention (162 mmHg, SD 7.3), control (160 mmHg, SD 6.9)
? Diastolic blood pressure: intervention (96 mmHg, SD 2.4), control (95 mmHg, SD 2.0)
? High Density Lipoproteines: (intervention 38 mg/dL, SD 3), control (39 mg/dL, SD 4)
? Trigycerides: intevention (236 mg/100 ml, SD 42), control (243 mg/100ml, SD 36)
? Low Density Lipoproteines: intervention (146 mg/dL, SD 10), control (146 mg/dL, SD 9)
? HbA1c: intervention (9.5 %, SD 1.6), control (9.6 %, SD 1.9)
? Retinopathy: intervention (11), control (10)
? Treatment modality: diet alone (intervention 18, control 16), diet + oral hypoglycaemic agent (intervention 43, control 46), diet + insulin (intervention 10, control 8) ";57,1;57,102;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Rosenkranz ;1996;Sex: group A (F: 14, M: 23), group B (F: 14, M: 21), group C (F: 12, M: 19);;"? 113 type 2 diabetes patients
? Single centre study with outpatients in a mixed rural and urban area in Germany.
? Group A (37), group B (35), group C (31)
? Sex: group A (F: 14, M: 23), group B (F: 14, M: 21), group C (F: 12, M: 19)
? Duration since diagnosis: group A (<5 years 15, 5?10y: 10, 11?20y: 6, > 20y: 6); group B (<5y: 5, 5?10y: 10, 11?20y: 12, >20y:6); group C: <5 y: 6, 5?10y: 17, 11?20y: 6, >20: 2 ";not reported;;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Simmons ;2000;Sex: intervention (F: 25, M: 11), control (F: 23, M: 9);both;"? 68 type 2 diabetes patients in a multi?centre study in an urban area in New?Zealand
? Sex: intervention (F: 25, M: 11), control (F: 23, M: 9)
? Age: intervention (55 years +? 11), control (53 years +? 11)
? Ethnicity: local (intervention 26, control 25)
? Weight: intervention (100,4 kg +? 24.3), control (104.1 kg +? 26.6)
? BMI: intervention (37.3 +? 8), control (38.5 +? 10.2)
? Systolic blood pressure: intervention (141 mmHg +? 16), control (142 mmHg +? 18)
? Diastolic blood pressure: intervention (83 mmHg +? 10), control (80 mmHg +? 9)
? HbA1c: intervention (9.9% +? 2.2), control (9.5 % +? 1.7)
? Insulin treated: intervention (2), control (5) ";54;54,059;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Skaer ;1993;Sex: I1 (F: 54, M: 25), I2 (F: 31, M:22), I3 (F:29, M: 19), control (F: 49, M: 29);both;"? Single centre study in the USA
? 258 Type 2 diabetes patients recruited from primary care services
? Participants : intervention I1 (79), I2 (53), I3 (48), control (78)
? Sex: I1 (F: 54, M: 25), I2 (F: 31, M:22), I3 (F:29, M: 19), control (F: 49, M: 29)
? Mean age: I1 (53.6 yrs, SD 7.7), I2 (51.8 yrs, SD 8.6), I3 (52.3 yrs, SD 8.4), control (51.7 yrs, SD 7.8)
? Treatment modality: oral hypoglycaemic agents: I1: 79, I2: 53, I3: 48, control: 78 ";52,35;52,413;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;Smith ;1986;Sex: intervention (F: 316, M: 113), control (F: 323, M: 107);both;"? 859 type 2 diabetes outpatients
? Single centre study in the USA
? Sex: intervention (F: 316, M: 113), control (F: 323, M: 107)
? Mean age: intervention (59.3 years +?12.5), control (59.0 yrs +? 13.2)
? Ethnicity: intervention (301 Black), control (300 Black)
? Systolic blood pressure: intervention (139 mmHg +?22), control (138 mmHg +? 22)
? Diastolic blood pressure: intervention (80 mmHg +? 12), control (79 mmHg +? 11)
? Random glycaemia: intervention (209 mg/dL +? 94), control (216 mg/dL +? 94)
? Treatment modality: oral hypoglycemic agents (intervention: 97, control: 120), insulin (intervention: 328, control: 304), combination (intervention: 4, control: 6) ";59,15;59,15;;;;;;;;;;;
69;https://doi.org/10.1002/14651858.CD003638.pub2;Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus;2005;21;White ;1986;Sex: men only;male;"? 32 type 2 diabetes outpatients
? Inclusion criteria: less than satisfactory control (FBG >140 mg/dl), infrequent hypoglycaemic reactions (<1/mo), no history of ketoacidosis, body weight >15% above the mean value for height, no history of alcohol abusus or severe personality disorder, and no current use of glucocorticoids.
? Sex: men only
? Age: intervention (62.4 years +? 5.5), control (60.7 years +? 6.4)
? Percentage of weight excess: intervention (36.3% +? 21.0), control (44.3% +? 21.0)
? Duration since diagnosis: intervention (10.2 years +? 12.9), control (13.6 years +? 9.6) ";61,55;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;Gruppe 1;Gruppe 2;Gruppe 3;Gruppe 4;Gruppe 5;Gruppe 6
;;;;;;;;;;;;;;;;Anzahl;1;1;;;;
;;;;;;;;;;;;;;;;Mittelwert;62,4;60,7;;;;
;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;62,4;60,7;0;0;0;0
;;;;;;;;;;;;;;;;61,55;;;;;;
